Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials

Publisher： Karger

E-ISSN： 1423-0267|236|4|193-200

ISSN： 0030-3755

Source： Ophthalmologica, Vol.236, Iss.4, 2016-10, pp. : 193-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration

By Patel Ravi D.   Momi Rominder S.   Hariprasad Seenu M.  

Seminars in Ophthalmology, Vol. 26, Iss. 6, 2011-11 ,pp. : 372-379

Informa Healthcare

Access to resources Recommend Favorite

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite

Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison

By  

Ophthalmologica, Vol. 232, Iss. 3, 2014-08 ,pp. : 149-155

Karger

Access to resources Recommend Favorite

Early Clinical Experience with Ranibizumab for Occult and Minimally Classic Neovascular Membranes in Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 222, Iss. 5, 2008-07 ,pp. : 321-323

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite